
 **2nd Annual Henry Ford Cancer Gastrointestinal & Neuroendocrine Multidisciplinary Symposium - 5/19/23 | 5/19/2023 7:30:00 AM The Henry Hotel**

Gastrointestinal & Neuroendocrine Symposium, providing the latest information on Germline Mutations, ctDNA Testing, Localized Pancreatic Cancer, Radiation, Metastatic Colorectal Cancer, Immunotherapies, and other topics in a multidisciplinary format.

**Program Goal**

1 To understand the impact of recent data from clinical trials on GI and NET cancer patient care.

2 To become informed on best practices in an integrated multimodality therapy for patients with GI cancers and NET tumors.

3 To use molecular diagnostic studies in the management of patients with GI and NET tumors.

**Target Audience** Medical Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Tressa Cuschieri, BBA | Activity Coordinator | Nothing to disclose - 01/13/2023 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 12/14/2022 |
| Christina Miller, BS | CME Specialist | Nothing to disclose - 01/18/2023 |
| Philip Philip, MD, PhD | Course Director, Faculty | Honoraria-Advisor, Speaker Beureau, |Consulting Fee-Stemline (Relationship has ended)|Honoraria-Lilly (Relationship has ended)|Grant or research support-Karyopharm (Relationship has ended)|Advisor-Pfizer (Relationship has ended)|Advisor-Seattle Genetics|Consulting Fee-Bayer|Grant or research support-Carcept (Relationship has ended)|Honoraria-Daiichi|Honoraria-Erytech|Honoraria-Incyte|Honoraria-Ipsen|Honoraria-Merck|Honoraria-Novocure (Relationship has ended)|Grant or research support-Rafael (Relationship has ended)|Honoraria-Genetech|Consulting Fee-Trisauls|Advisor-Boston Pharmaceuticals (Relationship has ended)|Honoraria-Servier - 01/13/2023 |
| Richard Berri, MD | Faculty | Nothing to disclose - 02/14/2023 |
| Sreenlvasa Chandana, MD | Faculty | Grant or research support-AbbVie|Grant or research support-Astrazeneca|Grant or research support-Exact Sciences|Grant or research support-Janssen|Grant or research support-Merck|Grant or research support-Novocure|Speakers Bureau-BMS (Relationship has ended)|Speakers Bureau-Natera|Advisor-Astrazeneca (Relationship has ended) - 02/09/2023 |
| Dhananjay Chitale, MD | Faculty | Nothing to disclose - 07/07/2022 |
| Katherine Cools, MD | Faculty | Nothing to disclose - 12/01/2022 |
| Maria Diab, MD, Assistant Professor | Faculty | Advisor-Novartis|Advisor-Guardant Health (Relationship has ended) - 02/15/2023 |
| Ahmed Kaseb, MD | Faculty | Honoraria-BMS|Consulting Fee-BMS|Honoraria-Genentech|Consulting Fee-Genentech|Honoraria-Astrazeneca|Consulting Fee-Astrazeneca|Honoraria-Eisai|Consulting Fee-Eisai|Honoraria-Exelixis|Consulting Fee-Exelixis|Grant or research support-BMS|Grant or research support-Genentech|Grant or research support-Astrazeneca|Grant or research support-Eisai|Grant or research support-Exelixis|Grant or research support-Adaptimmune|Grant or research support-Tvardi - 02/23/2023 |
| Gazala Khan, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eisai, Incyte, Helsinn - 02/09/2023 |
| Steve H Kim, MD, FACS | Faculty | Nothing to disclose - 02/07/2023 |
| David Kwon, MD | Faculty | Nothing to disclose - 01/03/2023 |
| Surya Nalamati, MD | Faculty | Nothing to disclose - 02/14/2023 |
| Parag Parikh, MD | Faculty | Speakers Bureau-Viewray|Grant or research support-Viewray - 02/10/2023 |
| Vaibhav Sahai, MBBS | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astrazeneca|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Autem Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Delcath Systems|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GSK (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Helsinn (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Histosonics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ipsen|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kinnate|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Amplity|Membership on Advisory Committees or Review Panels, Board Membership, etc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Taiho Pharmaceutical|Grant or research support-Actuate|Grant or research support-Agios (Relationship has ended)|Grant or research support-BMS|Grant or research support-Celgene (Relationship has ended)|Grant or research support-Clovis Oncology|Grant or research support-Cornerstone|Grant or research support-Exelixis|Grant or research support-Fibrogen|Grant or research support-Ipsen|Grant or research support-Incyte (Relationship has ended)|Grant or research support-Medimmune|Grant or research support-Relay|Grant or research support-Repare|Grant or research support-Syros|Other: Material (drugs) for lab work-Beigene - 02/05/2023 |
| Mohamed Salem, MD | Faculty | Speakers Bureau-Astrazeneca|Speakers Bureau-Taiho Pharmaceutical (Relationship has ended)|Speakers Bureau-Pfizer|Speakers Bureau-Daiichi Sankyo|Speakers Bureau-BMS|Honoraria-Exelixis (Relationship has ended)|Advisor-Squibb (Relationship has ended) - 02/16/2023 |
| Reena Salgia, MD | Faculty | Advisor-Eisai|Advisor-AstraZeneca|Advisor-Exelixis - 01/07/2023 |
| Rupen Shah, MD | Faculty | Consulting Fee-Cancer Study Group (Relationship has ended) - 12/22/2022 |
| Michael S Simon, MD, MPH | Faculty | Nothing to disclose - 02/14/2023 |
| Amy M Weise, DO | Faculty | Nothing to disclose - 01/25/2023 |
| Mark Zalupski, MD | Faculty | Nothing to disclose - 02/10/2023 |
| Kisha McPherson, MHSA | Other Planning Committee Member | Nothing to disclose - 01/13/2023 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT: Henry Ford Health System** is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**DESIGNATION STATEMENT: Henry Ford Health System** designates this educational activity for a maximum of 6.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In Compliance with the ACCME Standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own or spouse or partners with any ACCME defined commercial interests for the past 24 months and/or any non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated.

**ACCESSIBILITY STATEMENT:** Henry Ford Health System Office of Continuing Medical Education is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.